Inflammatory regulatory network mediated by the joint action of NF-kB, STAT3, and AP-1 factors is involved in many human cancers.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
07 05 2019
Historique:
pubmed: 27 3 2019
medline: 17 3 2020
entrez: 27 3 2019
Statut: ppublish

Résumé

Using an inducible, inflammatory model of breast cellular transformation, we describe the transcriptional regulatory network mediated by STAT3, NF-κB, and AP-1 factors on a genomic scale. These proinflammatory regulators form transcriptional complexes that directly regulate the expression of hundreds of genes in oncogenic pathways via a positive feedback loop. This transcriptional feedback loop and associated network functions to various extents in many types of cancer cells and patient tumors, and it is the basis for a cancer inflammation index that defines cancer types by functional criteria. We identify a network of noninflammatory genes whose expression is well correlated with the cancer inflammatory index. Conversely, the cancer inflammation index is negatively correlated with the expression of genes involved in DNA metabolism, and transformation is associated with genome instability. We identify drugs whose efficacy in cell lines is correlated with the cancer inflammation index, suggesting the possibility of using this index for personalized cancer therapy. Inflammatory tumors are preferentially associated with infiltrating immune cells that might be recruited to the site of the tumor via inflammatory molecules produced by the cancer cells.

Identifiants

pubmed: 30910960
pii: 1821068116
doi: 10.1073/pnas.1821068116
pmc: PMC6511065
doi:

Substances chimiques

DNA, Neoplasm 0
NF-kappa B 0
Neoplasm Proteins 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
Transcription Factor AP-1 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9453-9462

Subventions

Organisme : NCI NIH HHS
ID : K99 CA207865
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA207865
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA107486
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Genes Dev. 2006 Sep 15;20(18):2527-38
pubmed: 16980582
Cancer Cell. 2007 Mar;11(3):291-302
pubmed: 17349585
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
Crit Rev Oncol Hematol. 2009 Jun;70(3):183-94
pubmed: 18805702
Cell. 2009 Nov 13;139(4):693-706
pubmed: 19878981
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Cancer Cell. 2010 Apr 13;17(4):348-61
pubmed: 20385360
Mol Cell. 2010 Aug 27;39(4):493-506
pubmed: 20797623
Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1397-402
pubmed: 21220315
Cancer Res. 2011 Aug 1;71(15):5144-53
pubmed: 21670079
Nature. 2012 Mar 28;483(7391):603-7
pubmed: 22460905
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14470-5
pubmed: 22908280
Genome Res. 2013 Aug;23(8):1195-209
pubmed: 23595228
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Epigenetics Chromatin. 2015 Feb 14;8:7
pubmed: 25784959
Proc Natl Acad Sci U S A. 2015 May 5;112(18):5708-13
pubmed: 25902495
J Clin Invest. 2015 Sep;125(9):3384-91
pubmed: 26325035
Nat Commun. 2015 Dec 04;6:8971
pubmed: 26634437
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Cell. 2016 Jul 28;166(3):740-754
pubmed: 27397505
Genome Biol. 2016 Aug 22;17(1):174
pubmed: 27549193
Nat Commun. 2018 May 25;9(1):2068
pubmed: 29802342
Mol Cell Biol. 1998 May;18(5):2545-52
pubmed: 9566874

Auteurs

Zhe Ji (Z)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115.
Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.

Lizhi He (L)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115.

Aviv Regev (A)

Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142.
Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 20140.
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 20140.
Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 20140.

Kevin Struhl (K)

Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115; kevin@hms.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH